Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation...
On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell.
- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $573.0 million - - GAAP Diluted...
Barchart Research What to Expect from EXEL Earnings EXEL Generated August 4, 2026 Current Price $56.01 EPS Estimate $$0.75 Consensus Rating Moderate Buy Average Move 9.99% Can Exelixis Explain Why the...
Barchart Research What to Expect from EXEL Earnings EXEL Generated July 24, 2026 Current Price $55.37 EPS Estimate $$0.75 Consensus Rating Moderate Buy Average Move 9.99% Exelixis: When Your Entire Valuation...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –
Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver...
– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –
- Presentations to be webcast on www.exelixis.com -